相关实验视频

Updated: Jun 15, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

分析Tox21化合物库对它们对细胞染色体P450酶的抑制作用

Srilatha Sakamuru¹, Jameson Travers¹, Carleen Klumpp-Thomas¹

¹Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.

International journal of molecular sciences

|June 13, 2025

概括

这项研究选了环境化学物质,以抑制关键的药物代谢细胞染色体P450 (CYP) 酶. 研究人员确定了已知的抑制剂,并发现了新的选择性CYP抑制剂,有助于预测和减轻药物毒性.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
毒理学毒理学毒理学

背景情况:

细胞染色体P450 (CYP) 酶对于代谢药物和环境化学物质至关重要.
特定的CYP异型 (CYP1,2,和3家族) 负责代谢大约80%的药物.
了解环境化学物质对CYP的影响对于药物开发和安全至关重要.

研究的目的:

选Tox21 10K化合物库中抑制主要人类CYP酶 (CYP1A2,2C9,2C19,2D6和3A4) 的化学物质.
确定与多种或选择性CYP抑制相关的结构类.
为了发现新的强大的CYP抑制剂.

主要方法:

对Tox21 10K化合物库对五种关键人类CYP酶的选.
查数据的分析,以确定负责CYP抑制的化学结构.
确认已知的CYP抑制剂和识别具有强效活性 (IC50<1μM) 的新型抑制剂.

主要成果:

已确认的已知泛-CYP抑制剂 (例如,醇杀菌剂) 和选择性抑制剂 (例如,红色素,维拉帕米尔,帕洛克塞丁,特尔比纳芬).
鉴定出新的选择性CYP抑制剂,包括约欣宾 (CYP2D6抑制剂) 和洛特普雷德诺 (CYP3A4抑制剂).
对于新发现的选择性抑制剂,观察到强烈的活性 (IC50 < 1 μM).

结论:

该研究成功地确定了抑制关键药物代谢CYP酶的环境化学物质.
这些发现凸显了具有治疗或毒理影响的新型选择性CYP抑制剂的潜力.
评估化合物对CYP功能的影响可以帮助缓解药物不良反应和发育过程中的毒性.

关键词:

在CYP抑制剂中使用.在CYP1A2中.在CYP2C19中.在CYP2C9中.在CYP2D6中.在 CYP3A4 中.细胞染色体P450 (CYP) 的使用.量化高通量选 (qHTS) 是一种高通量选技术.

更多相关视频

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

相关概念视频

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Bioactivation and Tissue Toxicity

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...